124 related articles for article (PubMed ID: 10340605)
1. Synthesis and evaluation of geldanamycin-estradiol hybrids.
Kuduk SD; Zheng FF; Sepp-Lorenzino L; Rosen N; Danishefsky SJ
Bioorg Med Chem Lett; 1999 May; 9(9):1233-8. PubMed ID: 10340605
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of geldanamycin-testosterone hybrids.
Kuduk SD; Harris TC; Zheng FF; Sepp-Lorenzino L; Ouerfelli Q; Rosen N; Danishefsky SJ
Bioorg Med Chem Lett; 2000 Jun; 10(11):1303-6. PubMed ID: 10866406
[TBL] [Abstract][Full Text] [Related]
3. Design of quinolinedione-based geldanamycin analogues.
Hargreaves R; David CL; Whitesell L; Skibo EB
Bioorg Med Chem Lett; 2003 Sep; 13(18):3075-8. PubMed ID: 12941337
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
5. Control of estrogen receptor ligand binding by Hsp90.
Fliss AE; Benzeno S; Rao J; Caplan AJ
J Steroid Biochem Mol Biol; 2000 Apr; 72(5):223-30. PubMed ID: 10822011
[TBL] [Abstract][Full Text] [Related]
6. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes.
Schnaider T; Somogyi J; Csermely P; Szamel M
Life Sci; 1998; 63(11):949-54. PubMed ID: 9747895
[TBL] [Abstract][Full Text] [Related]
7. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
9. Radester, a novel inhibitor of the Hsp90 protein folding machinery.
Shen G; Blagg BS
Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158
[TBL] [Abstract][Full Text] [Related]
10. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Schnaider T; Somogyi J; Csermely P; Szamel M
Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Mimnaugh EG; Xu W; Vos M; Yuan X; Neckers L
Mol Cancer Res; 2006 Sep; 4(9):667-81. PubMed ID: 16966435
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton.
Galigniana MD; Scruggs JL; Herrington J; Welsh MJ; Carter-Su C; Housley PR; Pratt WB
Mol Endocrinol; 1998 Dec; 12(12):1903-13. PubMed ID: 9849964
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
Lawson B; Brewer JW; Hendershot LM
J Cell Physiol; 1998 Feb; 174(2):170-8. PubMed ID: 9428803
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
16. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
Goasduff T; Cederbaum AI
Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
[TBL] [Abstract][Full Text] [Related]
17. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
18. Biotinylated geldanamycin.
Clevenger RC; Raibel JM; Peck AM; Blagg BS
J Org Chem; 2004 Jun; 69(13):4375-80. PubMed ID: 15202892
[TBL] [Abstract][Full Text] [Related]
19. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
Blagosklonny MV
Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
Tian ZQ; Liu Y; Zhang D; Wang Z; Dong SD; Carreras CW; Zhou Y; Rastelli G; Santi DV; Myles DC
Bioorg Med Chem; 2004 Oct; 12(20):5317-29. PubMed ID: 15388159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
